Clinical trials: Drug Eluting Stents
Chronic Rhinosinusitis (CRS)
Product Surveillance Registry; Ear, Nose and Throat - EXTEND Cohort
The purpose of this study is to confirm long-term clinical safety and performance, acceptability of identified risks, and detect emerging risks based on factual evidence for the PROPEL family of products when used according to…
- Trial name
- NCT06671561
- Testing
- Observational data collection from patients with chronic rhinosinusitis (CRS) receiving PROPEL sinus implant(s) following functional endoscopic sinus surgery (FESS)
- Sponsor
- Medtronic
Coronary Artery Disease, Stable Angina
Comparison of Drug Eluting Balloon and Drug Eluting Stent
The purpose of this study is to evaluate the safety and efficacy of Drug-Eluting Balloon first and then bare metal stent compared with drug-eluting stent for treatment of de novo lesions (DEB first).
- Conditions
- Coronary Artery Disease, Stable Angina, Unstable Angina, NSTEMI
- Trial name
- DEBfirst (NCT01539603)
- Testing
- Drug eluting balloon + Bare metal stent, drug eluting stent (Zotarolimus-eluting stent)
- Where
- South Korea
- Volunteers
- 180 people
- Sponsor
- Seoul National University Bundang Hospital
Atrial Fibrillation New Onset, Acute Myocardial Infarction
Stent Placement and the Risk of New-onset AF in Patients With AMI
The benefit of a drug-eluting stent (DES) in patients with acute myocardial infarction (AMI) is controversial. This study will aim to observe the effect of a DES on the risk of new-onset AF in patients with AMI.
- Trial name
- NCT03382990
- Testing
- DES or BMS
- Volunteers
- 40,000 people
- Sponsor
- Mackay Memorial Hospital
Coronary Disease, Coronary Artery Disease
EXecutive Registry: Evaluating XIENCE V® in a Multi Vessel Disease
The purpose of this two part study is the assessment of the performance of the XIENCE V® Everolimus Eluting Coronary Stent System (XIENCE V® EECSS) in the treatment of the specific setting of patients with Multi-Vessel Coronary…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis
- Trial name
- EXecutive (NCT01310309)
- Testing
- Coronary artery placement of a drug-eluting stent
- Where
- 23 sites in Italy
- Volunteers
- 400 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease, Myocardial Ischemia
AVJ-301 Clinical Trial: A Clinical Evaluation of AVJ-301 (Absorb™ BVS) in Japanese Population
Prospective, Randomized (2:1), active control, single-blind, non-inferiority, multicenter, Japanese Clinical Trial to evaluate the safety and effectiveness of Absorb™ BVS (AVJ-301) in the treatment of subjects with ischemic heart…
- Trial name
- ABSORB JAPAN (NCT01844284)
- Testing
- XIENCE PRIME®/XIENCE Xpedition™, Absorb™ BVS
- Where
- 39 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Abbott Medical Devices
Coronary Stenosis
IRIS-BioFreedom Cohort in the IRIS-DES Registry
The objective of this study is to evaluate effectiveness and safety of BIOFREEDOM™ FAMILY stent in the "real world" daily practice as compared with other drug-eluting stents.
- Trial name
- IRISBioFreedom (NCT03190057)
- Testing
- BIOFREEDOM™ FAMILY stent
- Where
- 8 sites in South Korea
- Volunteers
- 218 people
- Sponsor
- Seung-Jung Park
Coronary Disease, Coronary Artery Disease
To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels
The purpose of this study is to determine the safety and clinical outcomes of the Absorb BVS for daily use in patients with de novo lesions in previously untreated vessels.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB UK (NCT01977534)
- Testing
- Absorb BVS
- Where
- 24 sites in United Kingdom
- Volunteers
- 1,005 people
- Sponsor
- Abbott Medical Devices
Coronary Artery, Stent Thrombosis
Mechanism Of Stent Thrombosis (MOST) Study
This study is designed to assess the pathophysiology of ST by studying the main procedural and anatomical factors involved in the genesis of ST such as those related to stent and the vascular wall, as well as to the individual…
- Conditions
- Coronary Artery, Stent Thrombosis, Platelet, Thrombus
- Trial name
- Most (NCT01410539)
- Testing
- OCT guided PCI, OCT guided medical therapy
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Careggi Hospital
Coronary Artery Disease
A Study to Evaluate the Impact of 11-month Ticagrelor Monotherapy Following One-month DAPT After PCI
PIONEER IV CHINA is sought to investigate the safety and efficacy of 11-month ticagrelor monotherapy following one-month dual antiplatelet therapy (DAPT) after HT Supreme drug-eluting stent system at 12 months follow-up.
- Trial name
- NCT05015699
- Testing
- HT Supreme
- Sponsor
- Sino Medical Sciences Technology Inc.
Coronary Artery Disease, Stable Angina
BMX Alpha Registry: a Post-market Registry of the BioMatrix Alpha TM
Prospective, multi-center, registry designed to enrol up to 2,000 patients in up to 35 International centers. All patients will receive a BioMatrix AlphaTM stent as per clinical practice and will be followed for 2 years for data…
- Conditions
- Coronary Artery Disease, Stable Angina, Ischemia, Acute Coronary Syndrome
- Trial name
- NCT02871622
- Testing
- BioMatrix AlphaTM
- Where
- United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Biosensors Europe SA
Coronary Disease, Coronary Artery Disease
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ZoMaxx™ II (NCT00140101)
- Testing
- ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent
- Where
- 92 sites in United States, Australia and 2 more
- Volunteers
- 1,099 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Drug-coated Balloon Treatment
Evaluation of the efficacy and clinical outcomes of drug-eluting balloon therapy in ticyaici coronary artery disease.
- Trial name
- DCB-ONE TR (NCT07794839)
- Testing
- drug coated balloon, drug eluting stent
- Where
- Turkey (Türkiye)
- Volunteers
- 1,000 people
- Sponsor
- Istanbul Mehmet Akif Ersoy Educational and Training Hospital
In-Stent Restenosis
RIBS V (Restenosis Intra-stent of Bare Metal Stents: Paclitaxel-eluting Balloon vs Everolimus-eluting Stent)
Treatment of patients with bare metal stent restenosis remains a challenge. This study will assess which interventional strategy (paclitaxel-eluting balloon vs everolimus-eluting stent) is superior in the treatment of patients…
- Trial name
- RIBS V (NCT01239953)
- Testing
- Coronary angioplasty using the paclitaxel-eluting balloon, Coronary angioplasty using the everolimus-eluting stent
- Where
- 25 sites in Spain
- Volunteers
- 190 people
- Sponsor
- Fundación Médica para la Investigación y Desarrollo en el Area Cardiovascular
Coronary Restenosis
Treatment of in-Stent Restenosis by Paclitaxel Coated PTCA Balloons (PACCOCATH - ISR II)
The PACCOCATH ISR II study is a randomized, double-blinded German multicenter trial on the efficacy and tolerance of a paclitaxel coated balloon catheter in coronary in-stent restenosis.
- Trial name
- NCT00409981
- Testing
- paclitaxel coated balloon catheter (device with drug)
- Where
- 5 sites in Germany
- Volunteers
- 56 people
- Sponsor
- University Hospital, Saarland
Coronary Disease, Coronary Artery Disease
ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation
Prospective, open-labeled First in Man Clinical Investigation enrolling patients with visually estimated nominal vessel diameter of 3.0 mm receiving a single 3.0 x 12 mm or 3.0 x 18 mm BVS EECSS containing 98 microgramme per cm²…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB A (NCT00300131)
- Testing
- Bioabsorbable Everolimus Eluting Coronary Stent
- Where
- 4 sites in Denmark, Netherlands and 2 more
- Volunteers
- 30 people
- Sponsor
- Abbott Medical Devices
Myocardial Infarction, Ischemia
FIT (Fast Infarction Treatment): Complete Revascularization During Primary Percutaneous Coronary Intervention (PCI) Can be Achieved Safely With an Improved Clinical Outcome During the Indexed Hospitalization.
Few reports described outcomes of complete compared with infarct related artery (IRA) only revascularization in patients with ST elevation myocardial infarction (STEMI) and multivessel coronary disease (CAD).
- Conditions
- Myocardial Infarction, Ischemia, Heart Failure, Necrosis
- Trial name
- FIT (NCT01160900)
- Testing
- Coronary angioplasty all lesions
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Azienda Ospedaliera San Camillo Forlanini
Angiospastic; Disorder
Safety Assessment of Angioplasty Procedures
Ischemic heart disease, or coronary heart disease, covers a set of pathologies due to insufficient oxygen supply to the myocardium due to the development of atherosclerosis in one or more coronary arteries.
- Trial name
- SCRAP (NCT03893396)
- Testing
- Coronary angioplasty
- Where
- France
- Volunteers
- 983 people
- Sponsor
- Groupe Hospitalier de la Rochelle Ré Aunis
Coronary Artery Disease
The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions in Small Vessels
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM SV (NCT01498692)
- Testing
- PROMUS Element Coronary Stent System
- Where
- 23 sites in United States, Australia and 4 more
- Volunteers
- 94 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Valsartan for Suppression of Plaque Volume and Restenosis After Drug-Eluting Stent
To evaluate that angiotensin-converting enzyme (ACE) inhibitors and angiotensin-converting enzyme receptor blockers (ARBs) reduce the risk of restenosis after DES implantation.
- Trial name
- VAL-SUPPRES (NCT00589732)
- Testing
- Valsartan
- Where
- 5 sites in South Korea
- Volunteers
- 220 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Israel Satellite Registry
BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus Eluting Orsiro Stent System Within daily clinical practice - III
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01895712
- Where
- 6 sites in Israel
- Volunteers
- 120 people
- Sponsor
- BIOTRONIK Israel